Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
19 firms currently rating it, weighted by track record.
The 17 firms with a track record here beat the S&P 41% of the time over 12 months.
Pro: see the crowd-vs-sharp split for JNJAnalysts rate Johnson & Johnson a consensus Buy, with 16 of 22 analysts rating it Buy or stronger and an average price target of $270.59, implying 2.7% upside from $263.40. Morgan Stanley upgraded the stock to Overweight in January, and most recent July ratings from Guggenheim, Raymond James, RBC Capital Markets, Wells Fargo, and Morgan Stanley maintained positive stances. The healthcare giant trades at a trailing P/E of 30.59 with a forward P/E of 20.53, posting 6.6% revenue growth year-over-year but flat EPS growth at negative 0.9%, while returning 25.74% ROE and carrying a low 0.58 debt-to-equity ratio.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 17, 2026 | Guggenheim | ○ Reiterated | |
| Jul 16, 2026 | Raymond James | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free